No validated shared molecular target between enlicitide decanoate and levothyroxine

The entry 'No validated shared molecular target between enlicitide decanoate and levothyroxine' is a descriptive pharmacological statement rather than a specific biological target, receptor, or enzyme. It indicates that there is no known molecular entity common to the mechanisms of action of these two distinct drugs. Enlicitide decanoate (also known as MK-0616) is an investigational oral macrocyclic peptide that functions as a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor, primarily used to treat hypercholesterolemia by preventing the degradation of LDL receptors (Source: PubMed, PMID: 37116313). Levothyroxine is a synthetic form of the thyroid hormone thyroxine (T4) that acts as an agonist at thyroid hormone receptors (THRA and THRB) to manage hypothyroidism (Source: PubChem CID 5819). While both drugs share a clinical requirement for administration on an empty stomach to optimize absorption, they do not interact with the same molecular targets or biological pathways. Consequently, this string serves as a negative finding in drug-target interaction databases rather than a valid target name.

Not applicable